On April 12, 2024 Nerviano Medical Sciences and the NMS Group affiliates Accelera and NerPharMa, reported that it will participate in the SWISS BIOTECH DAY 2024 partnering event, which will be held in the Congress Center Basel, Switzerland on April 22-23, 2024 (Press release, Nerviano Medical Sciences, APR 12, 2024, View Source [SID1234642035]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Come to visit us at the Delegation of Italy booth in the Global Village to discuss potential collaborations and partnering opportunities.

On April 12, 2024 Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, reported that its strategic collaboration with Genentech entered in 2021, has been terminated (Press release, Adaptimmune, APR 12, 2024, View Source [SID1234642034]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: "We’ve had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform. Over the past 12 months, we’ve been resolutely focused on our late-stage autologous pipeline – in particular, our sarcoma franchise. We have the resources to deliver afami-cel to market as planned, and I look forward to updating on progress at our Investor Day next week."

On April 11, 2024 Sprint Bioscience reported that previously unpublished results from the company’s DISA program targeting the protein TREX1 will be presented at the conference "Immuno-Oncology Summit Europe 2024" in London, England, 23 – 25 April 2024. The positive results from an in vivo proof-of-concept study show that treatment with the company’s TREX1 inhibitors results in an improved immune response and inhibited tumor growth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results show that oral administration of the company’s TREX1 inhibitors reduced tumor growth in an animal model of colorectal cancer and at the same time increased the recruitment of immune cells to the tumors.

"Targeting TREX1 represents a novel approach to amplifying the immune response, with a mechanism that is different from existing approved immunotherapies. When blocking TREX1 in tumors, the body’s immune response is reactivated, resulting in inhibition of tumor growth. Our data support the therapeutic hypothesis in this program, and we look forward to presenting the program to scientists and potential partners in the immuno-oncology field." said Martin Andersson, CSO at Sprint Bioscience.

New publications show that the function of the TREX1 protein in cancer cells inhibits the immune response. This, in combination with the company’s data, confirms the hypothesis that TREX1 is an interesting new target for cancer therapy.

The poster "Inhibition of TREX1 Increases Interferon Signaling and Reduces Tumor Growth In Vivo" is presented by Camilla Silvander, PhD, Director Protein Science, Sprint Bioscience.

(Press release, Sprint Bioscience, APR 11, 2024, View Source [SID1234660962])

On April 11, 2024 LaNova Medicines Ltd. reported the initiation of its first Phase III clinical trial for LM-302 (anti-Claudin 18.2 ADC) in China (Press release, LaNova Medicines, APR 11, 2024, View Source [SID1234655991]). This marks the first antibody-drug conjugate candidate in LaNova’s pipeline to enter the pivotal clinical study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical study (CTR20240955) is a randomized, open-label, multi-center, positive-controlled Phase III trial primarily assessing the efficacy and safety of LM-302 in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma who are CLDN18.2 positive.

On April 11, 2024 Orion reported its interim report January to March 2024 (Presentation, Orion, APR 11, 2024, View Source [SID1234646732]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!